Outcome of Imatinib treatment in Yemeni patients with chronic myeloid leukemia and the influence of non-adherence to treatment and duration of prior hydroxyurea therapy

In a developing country like Yemen, data are limited regarding the outcome of Imatinib treatment of chronic myeloid leukemia and the impact of non-adherence to Imatinib and prior duration of hydroxyurea.

Source: Clinical Lymphoma, Myeloma and Leukemia - December 30, 2019 Category: Hematology Authors: Jameel Al-Ghazaly, Waled Al-Dubai, Yousr Noaman, Munasser Abdullah, Leila Al-Gharasi, Gianantonio Rosti Tags: Original Study Source Type: research